Trial Profile

A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of JPB898 (proposed Nivolumab Biosimilar) and US-licensed and EU-authorized Opdivo in Combination with Yervoy in Participants with Untreated Advanced (unresectable/metastatic) Melanoma

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 10 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 Feb 2026 Status changed from suspended to discontinued.
07 Aug 2025 Planned End Date changed from 31 Jul 2027 to 1 Feb 2026.
07 Aug 2025 Planned primary completion date changed from 31 Jul 2027 to 1 Feb 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com